← Back to Pipeline
Clinical Phase IINIH / NIAPrincipal Investigator
EMRAST
Early Multi-Modal Alzheimer's Risk Assessment & Sensing Technology
Multimodal diagnostic platform combining psychophysical olfactory stimulation with ML-based biomarker classification for pre-clinical Alzheimer's detection. Randomized feasibility trial published in Alzheimer's & Dementia.
$2.95MR44AG082621
Project Facts
- Role
- Principal Investigator
- Phase
- Phase II
- Status
- Clinical Validation
- Funding
- $2.95M
- Grant Number
- R44AG082621
- Agency
- NIH / NIA
NIH Award History
$449KPhase I2023
1R44AG082621-01
$1.25MPhase II2024
4R44AG082621-02
$1.25MPhase II2025
5R44AG082621-03
Engineering Challenges
- Designing calibrated, reproducible olfactory stimulus delivery across diverse clinical environments
- Integrating multi-modal physiological sensing within a standardized clinical workflow
- Developing ML classification models robust to real-world measurement variability
- Building FDA Design History File architecture alongside rapid iterative development
- Ensuring patient compliance across populations with varying cognitive status
Technology Domains
BioelectronicsMachine LearningFDA 21 CFR 820ISO 13485Signal ProcessingHIPAA Architecture
Intellectual Property
Alzheimer's & Dementia: TR&CI
Randomized feasibility clinical trial (Article TRC270226)
View reference →